Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022, at 3:00 PM EDT in Toronto. CEO Dr. Fahar Merchant and CFO Elizabeth Williams will provide a corporate overview. This conference connects investors with updates from prominent Canadian healthcare companies. Medicenna focuses on immunotherapy advancements, including its long-acting IL-2 Superkine, MDNA11, and IL-4 Empowered Superkine, MDNA55, which is undergoing clinical trials for recurrent GBM.
- None.
- None.
TORONTO and HOUSTON, April 27, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President and CEO and Elizabeth Williams, CFO of Medicenna, will attend the conference and present a corporate overview at the 2022 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place from May 2 – May 3, 2022.
Details are as follows:
| 2022 Bloom Burton & Co. Healthcare Investor Conference | ||
| Date: | Monday, May 2nd | |
| Time: | 3:00pm EDT | |
| Location: | Metro Toronto Convention Centre, North Building, | |
| 255 Front St W, Toronto, Ontario | ||
| Webcast: | Webcast Link | |
Webcast and replay information for this event will be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/.
Bloom Burton & Co. Healthcare Investor Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.
FAQ
When is Medicenna presenting at the 2022 Bloom Burton & Co. Healthcare Investor Conference?
Who will represent Medicenna at the conference?
Where is the 2022 Bloom Burton & Co. Healthcare Investor Conference held?
What is the focus of Medicenna's research and development?
What is MDNA55 and its clinical significance?
